
Raymond James analyst Tiago Fauth initiated coverage of Avalyn Pharma (AVLN) with an Outperform rating and $60 price target Avalyn is developing inhaled formulations of the two most clinically validated
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc | 30.28 | 0.79 | 2.68% |
| Name | Price | % Change | |
|---|---|---|---|
| $30.28 | +2.68% |

Raymond James analyst Tiago Fauth initiated coverage of Avalyn Pharma (AVLN) with an Outperform rating and $60 price target Avalyn is developing inhaled formulations of the two most clinically validated

Avalyn Pharma (AVLN) announced that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02 in healthy volunteers and patients with IPF. Topline data from the

New option listings for August 21st include Avalyn Pharma Inc (AVLN). Option delistings effective August 21st include Liberty Broadband (LBRDK) and Liberty Broadband (LBRDA). Published first on TheFly – the

New option listings for August 21st include Avalyn Pharma Inc (AVLN). Option delistings effective August 21st include Liberty Broadband (LBRDK) and Liberty Broadband (LBRDA). Published first on TheFly – the

Morgan Stanley raised the firm’s price target on Avalyn Pharma (AVLN) to $57 from $53 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate

Avalyn Pharma (AVLN) announced that it has completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 in patients with progressive pulmonary fibrosis. Additional patients

SpaceX and OpenAI are moving toward blockbuster public debuts, with SpaceX formally filing its Form S 1 to list on Nasdaq under the ticker “SPCX” in what could become the

Evercore ISI analyst Gavin Clark-Gartner initiated coverage of Avalyn Pharma (AVLN) with an Outperform rating and $51 price target Avalyn has “a strong respiratory pipeline” and the characteristics to be

Morgan Stanley initiated coverage of Avalyn Pharma (AVLN) with an Overweight rating and $53 price target The company is well positioned to address the “pressing unmet needs” of pulmonary fibrosis

Guggenheim analyst Seamus Fernandez initiated coverage of Avalyn Pharma (AVLN) with a Buy rating and $80 price target The firm has “high conviction” in the “multi-blockbuster sales” potential for Avalyn’s
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.